DermatologyNews.net

Dermatology Xagena

Xagena Mappa
Medical Meeting
Onco News
Farmaexplorer.it

New findings on Apremilast ( Otezla ), a selective inhibitor of phosphodiesterase 4 ( PDE4 ), from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis were presen ...


Tofacitinib ( Xeljanz ) is a novel, oral Janus kinase inhibitor currently under investigation for plaque psoriasis. This exploratory analysis of a phase IIb, 12-week, dose-ranging study has evaluat ...


Vismodegib ( Erivedge ), a first-in-class Hedgehog pathway inhibitor, was Food and Drug Administration ( FDA ) approved for advanced basal cell carcinomas ( BCCs ) based on a single, nonrandomized, ph ...


OBSERVE-5 was a 5-year FDA-mandated surveillance registry of patients with psoriasis. Researchers have assessed long-term Etanercept ( Enbrel ) safety and effectiveness. Patients with moderate to s ...


Vismodegib ( Erivedge ), the first Food and Drug Administration ( FDA )-approved Hedgehog ( Hh ) signaling pathway inhibitor, in the treatment of advanced basal cell carcinoma ( BCC ). Activation o ...


A phase III study of the combination of Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), compared to single agent therapy with Dabrafenib in patients with BRAF V600 E or K mutation positive unrese ...


Fungal skin infections, or dermatomycoses, are associated with a broad range of pathogens. Involvement of gram-positive bacteria is often suspected in dermatomycoses. Inflammation plays an important r ...


Apremilast ( Otezla ), a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-inflammatory cytokine production. Apremilast's effect on patient-reported outcomes ( PROs ) i ...


Patients with advanced melanoma, who have been treated with the monoclonal antibody, Ipilimumab ( Yervoy ), can survive for up to ten years, according to the largest analysis of overall survival for t ...


Psoriasis is a common and chronic immune-mediated inflammatory disease of the skin affecting approximately 2% of individuals of European descent with a strong genetic susceptibility. Classic lesions ...


Many patients with chronic idiopathic urticaria ( also called chronic spontaneous urticaria ) do not have a response to therapy with H1-antihistamines, even at high doses. In phase 2 trials, Omalizuma ...


The results from the head-to-head phase III FIXTURE study showing Secukinumab ( AIN457 ), an interleukin-17A ( IL-17A ) inhibitor, was significantly superior to Etanercept ( Enbrel ) in moderate-to-se ...


Nivolumab, a human immunoglobulin G4-blocking antibody against the T-cell programmed death-1 checkpoint protein, has activity against metastatic melanoma. Its safety, clinical efficacy, and correlativ ...


The European Commission has granted conditional approval to Erivedge ( Vismodegib ) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma ( BCC ) or locally advanced BCC ...


The results from the phase 3 trial in melanoma, which has evaluated the efficacy and safety of Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to trea ...